Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorder Clear all

Conditions: Cardiac Arrythmias, Syncope, Atrial Fibrillation, Atrial Flutter, Tachycardia, Stroke
Interventions: Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM; Device
Lead sponsor: Sparrow Clinical Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Lansing, Michigan • Traverse City, Michigan

Conditions: Uncontrolled Hypertension
Interventions: Resource information, Community Health Worker (CHW) assistance, Medically-tailored Meals (MTM); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Age-Related Macular Degeneration
Interventions: PST, ST; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Encopresis, ASD
Interventions: Glycerin Suppository, Behavioral strategies; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Nutritional Deficiency
Interventions: Education on Female Athlete Nutritional Concerns; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Musculoskeletal Pain
Interventions: omega 7, Placebo; Dietary Supplement
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Non-Hodgkin Lymphoma
Interventions: CC-122, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: New York, New York • Nashville, Tennessee • Madison, Wisconsin

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Opioid Withdrawal (Disorder)
Interventions: Lofexidine, Placebo; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Placentia, California • Rancho Mirage, California • Plantation, Florida + 9 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
Interventions: Mindfulness Based Stress Reduction (MBSR), Control; Behavioral · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cocaine Dependence
Interventions: SYN117 Placebo, SYN117 80 mg, SYN117 160 mg, Cocaine 10mg, Cocaine 20mg, Cocaine 40mg, Saline; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Chronic Hepatitis B
Interventions: Adefovir Dipivoxil for oral suspension, 2 mg/mL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Foster City, California

Conditions: Prostate Cancer
Interventions: Survey Administration; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Paclitaxel, NOV-002, Carboplatin; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 12
States / cities: Muscle Shoals, Alabama • San Diego, California • Chicago, Illinois + 9 more

Conditions: Asthma
Interventions: Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 52
States / cities: Scottsboro, Alabama • Glendale, Arizona • Phoenix, Arizona + 42 more

Conditions: Dry Mouth, Xerostomia, OSA, Sleep Apnea
Interventions: Test Oral Spray, Placebo Oral Spray; Device
Lead sponsor: You First Services; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acute Pain, Analgesia
Interventions: Placebos, Baclofen 5 mg, Baclofen 10mg; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Migraine, Traumatic Brain Injury, Anomalous Health Incidents
Interventions: Xeomin (incobotulinumtoxinA); Drug
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: abatacept; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 7
States / cities: Anniston, Alabama • Palm Harbor, Florida • Wheaton, Maryland + 4 more

Conditions: SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions: BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Long Beach, California • San Diego, California • Milford, Connecticut + 10 more

Conditions: Pre-diabetes, Overweight, Metabolic Syndrome
Interventions: Diabetes Genetic Counseling, No genetic counseling; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Hypertension
Interventions: Telemonitors and pharmacy management; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study

Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity

Improving Function in Age-Related Macular Degeneration

Comprehensive Toileting Program

Knowledge of Nutritional Concerns in Physically Active Females

Omega 7 Oil and Inflammatory Biomarker Study

A Rollover Study of CC-122

Quality of Life in IPF - Patient and Physician Perceptions

Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

Mindfulness Based Stress Reduction in Rheumatic Diseases

Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

"Hyaluronan" Formulation for Dry Mouth in Sleep Apnea Patients

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers

Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Genetic Counseling and Lifestyle Change for Diabetes Prevention

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Home Blood Pressure Telemonitoring and Case Management to Control Hypertension